Onward Therapeutics, a Taipei-based developer of cancer treatments, has closed a Series B round of NT$900m (about $28m). It announced the financing on 17 November 2026 in a release issued jointly from Taipei, Epalinges in Switzerland and Paris.
The round closed in two tranches, the second of them in October 2026. It is the company's first capital increase since a share exchange in October 2025 moved its global headquarters from Switzerland to Taiwan. No lead investor or valuation was disclosed.
Existing shareholders CDIB Capital Healthcare Ventures and Hong Kong Chlitina International took part, along with other individual and institutional shareholders. The new institutional investors were Beiley Biofund, Everbright Biofund, Test Rite International, Grand Fortune Venture Capital, Hercules Bioventure Partners, MitoBitTech Venture and Top Taiwan Venture Capital, and several individuals also joined.
“This financing, our first since establishing our global headquarters in Taiwan, allows us to advance our clinical programs while building our R&D presence here.”C. Grace Yeh, Chairperson and CEO, Onward Therapeutics
What Onward Therapeutics does
Onward was founded in November 2019 and has teams in Switzerland and France as well as its Taiwan headquarters. It is led by chairperson and chief executive C. Grace Yeh. Armand de Gramont, one of its three co-founders, moved from chief scientific officer to president of research and development in April 2026.
The company has two programmes in clinical trials and two at an earlier stage. OT-A201 is a tetravalent bispecific antibody, a molecule designed to bind two targets at once. In solid tumours it has completed monotherapy dose escalation and moved into Phase 1b, where Onward plans expansion groups for particular cancers and combination regimens. In blood cancers, it expects to finish enrolling a Phase 1a study by the end of 2026.
OT-C001 is an off-the-shelf natural killer (NK) cell therapy derived from umbilical cord blood. It is being tested with the antibody rituximab in a Phase 1 trial in France for people with relapsed or refractory diffuse large B-cell lymphoma who have already received CAR-T and T-cell engager therapies. Onward said early data showed the treatment was well tolerated and that several patients had complete metabolic responses. Pulse 2.0 noted that such early observations still need to be confirmed in further trials.
The two early programmes are OT-S00X, a small-molecule project aimed at cancer metabolism, and OT-A30X, an antibody programme against tumour-associated antigens.
What the money is for
Onward said the proceeds will pay for its clinical programmes, the manufacture of clinical trial supplies and early-stage research. It also plans to enlarge its team in Taiwan and to start clinical trials there. The release did not say how the money would be divided between programmes, and the amounts put in by individual investors were not disclosed.
Yeh said many patients with relapsed or hard-to-treat cancers still have few treatment options. De Gramont said the company's priority was turning its science into clinical results, and, according to Pulse 2.0, that it was concentrating on indications where its therapies could best overcome resistance to treatment.
The funding so far and listing plans
Before the 2025 share exchange, Onward had raised CHF 75.5m (about $90m, by the company's conversion) across earlier rounds. The release did not break that total down by round or name the earlier investors beyond the current shareholders.
The company has signed a listing advisory agreement with a securities firm and has started preparing to register on the Taipei Exchange's Emerging Stock Board, with a target of the end of 2027. It remains privately held, and its headcount was not disclosed.
Company website: onward-therapeutics.com
